News | November 03, 2021
Venus Remedies H1 net profit rises 315%
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
This unique record was made possible by collating hard copies of the books in a structured manner
Key takeaways of recent quarter & conference call highlights
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
The company claims that its Empagliflozin tablets are the most affordable in India
Equity raise to finance growth and investments in the biological space
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Subscribe To Our Newsletter & Stay Updated
